Galaxy Oncology Associates Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 19-05-2024
- Paid Up Capital ₹ 3.62 Cr
as on 19-05-2024
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 Cr
as on 19-05-2024
- Satisfied Charges ₹ 12.00 Cr
as on 19-05-2024
- Revenue -21.36%
(FY 2023)
- Profit -1544.49%
(FY 2023)
- Ebitda -838.21%
(FY 2023)
- Net Worth -46.94%
(FY 2023)
- Total Assets 69.06%
(FY 2023)
About Galaxy Oncology Associates
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.62 Cr.
The company currently has active open charges totaling ₹3.50 Cr. The company has closed loans amounting to ₹12.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Umang Mithal, Pragati Agarwal, and Sachin Kumar serve as directors at the Company.
- CIN/LLPIN
U85110DL2006PTC154903
- Company No.
154903
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 2006
- Date of AGM
12 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Galaxy Oncology Associates?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pragati Agarwal  | Managing Director | 28-Mar-2017 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Umang Mithal | Director | 08-Aug-2022 | Current |
| Sachin Kumar | Director | 29-Dec-2022 | Current |
Financial Performance of Galaxy Oncology Associates.
Galaxy Oncology Associates Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 21.36% decrease. The company also saw a substantial fall in profitability, with a 1544.49% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Galaxy Oncology Associates?
In 2023, Galaxy Oncology Associates had a promoter holding of 50.13% and a public holding of 49.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Feb 2023 | ₹1.60 Cr | Open |
Others Creation Date: 20 Sep 2022 | ₹1.90 Cr | Open |
Bank Of India Creation Date: 15 Dec 2007 | ₹12.00 Cr | Satisfied |
How Many Employees Work at Galaxy Oncology Associates?
Unlock and access historical data on people associated with Galaxy Oncology Associates, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Galaxy Oncology Associates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Galaxy Oncology Associates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
